Platinum Investment Management Ltd. Acquires 287 Shares of Jazz Pharmaceuticals PLC $JAZZ

Platinum Investment Management Ltd. raised its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 13.9% in the 2nd quarter, Holdings Channel.com reports. The firm owned 2,355 shares of the specialty pharmaceutical company’s stock after buying an additional 287 shares during the quarter. Platinum Investment Management Ltd.’s holdings in Jazz Pharmaceuticals were worth $250,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Hurley Capital LLC bought a new position in Jazz Pharmaceuticals during the first quarter valued at $25,000. Parallel Advisors LLC lifted its position in Jazz Pharmaceuticals by 85.6% during the first quarter. Parallel Advisors LLC now owns 258 shares of the specialty pharmaceutical company’s stock valued at $32,000 after purchasing an additional 119 shares during the last quarter. Spire Wealth Management lifted its position in Jazz Pharmaceuticals by 137.6% during the first quarter. Spire Wealth Management now owns 278 shares of the specialty pharmaceutical company’s stock valued at $35,000 after purchasing an additional 161 shares during the last quarter. Picton Mahoney Asset Management lifted its position in Jazz Pharmaceuticals by 2,445.5% during the first quarter. Picton Mahoney Asset Management now owns 280 shares of the specialty pharmaceutical company’s stock valued at $34,000 after purchasing an additional 269 shares during the last quarter. Finally, SVB Wealth LLC bought a new position in Jazz Pharmaceuticals during the first quarter valued at $36,000. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Trading Up 3.9%

Shares of JAZZ opened at $136.90 on Thursday. Jazz Pharmaceuticals PLC has a 1-year low of $95.49 and a 1-year high of $148.06. The company has a 50-day moving average of $122.95 and a 200 day moving average of $115.86. The firm has a market capitalization of $8.30 billion, a price-to-earnings ratio of -20.34, a PEG ratio of 8.17 and a beta of 0.28. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.62 and a quick ratio of 1.37.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($5.61) by ($2.64). Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The company had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $1.05 billion. During the same quarter in the previous year, the business earned $5.30 EPS. The company’s quarterly revenue was up 2.1% compared to the same quarter last year. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. On average, research analysts expect that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on JAZZ. Royal Bank Of Canada raised their target price on shares of Jazz Pharmaceuticals from $145.00 to $151.00 and gave the stock an “outperform” rating in a report on Thursday, August 28th. Deutsche Bank Aktiengesellschaft began coverage on shares of Jazz Pharmaceuticals in a report on Tuesday, July 15th. They issued a “buy” rating and a $152.00 target price for the company. The Goldman Sachs Group raised their target price on shares of Jazz Pharmaceuticals from $162.00 to $185.00 and gave the stock a “buy” rating in a report on Friday, August 29th. Truist Financial raised their target price on shares of Jazz Pharmaceuticals from $200.00 to $205.00 and gave the stock a “buy” rating in a report on Thursday, August 28th. Finally, Needham & Company LLC restated a “buy” rating and issued a $202.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, August 28th. Fourteen analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, Jazz Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $178.93.

Insiders Place Their Bets

In related news, Director Bruce C. Cozadd sold 6,000 shares of Jazz Pharmaceuticals stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $128.62, for a total transaction of $771,720.00. Following the completion of the sale, the director owned 429,973 shares in the company, valued at $55,303,127.26. This trade represents a 1.38% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 4.30% of the stock is owned by insiders.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.